TARS — Tarsus Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $2.08bn
- $1.86bn
- $182.95m
- 56
- 10
- 99
- 55
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.26 | ||
| Price to Tang. Book | 9.62 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 11.36 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -41.34% | ||
| Return on Equity | -54.83% | ||
| Operating Margin | -66.96% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 57.03 | 25.82 | 17.45 | 182.95 | 368.02 | 532.4 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The Company is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.
Directors
- Michael Ackermann NEC (39)
- Bobak Azamian PRE (43)
- Leo Greenstein CFO (45)
- Seshadri Neervannan COO (53)
- Dianne Whitfield CHO (44)
- Aziz Mottiwala CCO (43)
- Mark Holdbrook VPR (67)
- Bryan Wahl GCN (43)
- Jose Trevejo OTH
- Elizabeth Yeu-lin DRC
- Bhaskar Chaudhuri IND (67)
- Rosemary Crane IND (56)
- Andrew Goldberg IND (39)
- William Link IND (74)
- Jason Tester IND (45)
- Wendy Yarno IND (66)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 17th, 2016
- Public Since
- October 16th, 2020
- No. of Shareholders
- 27
- No. of Employees
- 323
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 41,580,162
- Address
- 15440 Laguna Canyon Road, IRVINE, 92618
- Web
- https://www.tarsusrx.com/
- Phone
- +1 9494099820
- Auditors
- Ernst & Young LLP
Upcoming Events for TARS
Q1 2025 Tarsus Pharmaceuticals Inc Earnings Call
Tarsus Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 Tarsus Pharmaceuticals Inc Earnings Release
Similar to TARS
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Tarsus Pharmaceuticals share price?
As of Today at 23:35 UTC, shares in Tarsus Pharmaceuticals are trading at $50.00. This share price information is delayed by 15 minutes.
How has the Tarsus Pharmaceuticals share price performed this year?
Shares in Tarsus Pharmaceuticals last closed at $50.00 and the price had moved by +55.23% over the past 365 days. In terms of relative price strength the Tarsus Pharmaceuticals share price has outperformed the S&P500 Index by +43.28% over the past year.
What are the analyst and broker recommendations for Tarsus Pharmaceuticals?
The overall consensus recommendation for Tarsus Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Tarsus Pharmaceuticals dividend yield?
Tarsus Pharmaceuticals does not currently pay a dividend.
Does Tarsus Pharmaceuticals pay a dividend?
Tarsus Pharmaceuticals does not currently pay a dividend.
When does Tarsus Pharmaceuticals next pay dividends?
Tarsus Pharmaceuticals does not currently pay a dividend.
How do I buy Tarsus Pharmaceuticals shares?
To buy shares in Tarsus Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Tarsus Pharmaceuticals?
As of the previous close price of $50.00, shares in Tarsus Pharmaceuticals had a market capitalisation of $2.08bn.
Where are Tarsus Pharmaceuticals shares listed?
Here are the trading details for Tarsus Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: TARS
What kind of share is Tarsus Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Tarsus Pharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Tarsus Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Tarsus Pharmaceuticals is $68.86. That is 37.72% above the last closing price of $50.00.
Analysts covering Tarsus Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$1.35 for the next financial year.
Find out moreWhat is the trend in the Tarsus Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Tarsus Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +33.72%.
As of the last closing price of $50.00, shares in Tarsus Pharmaceuticals were trading +19.44% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Tarsus Pharmaceuticals PE Ratio?
The Tarsus Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $50.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals' management team is headed by:
- Michael Ackermann - NEC
- Bobak Azamian - PRE
- Leo Greenstein - CFO
- Seshadri Neervannan - COO
- Dianne Whitfield - CHO
- Aziz Mottiwala - CCO
- Mark Holdbrook - VPR
- Bryan Wahl - GCN
- Jose Trevejo - OTH
- Elizabeth Yeu-lin - DRC
- Bhaskar Chaudhuri - IND
- Rosemary Crane - IND
- Andrew Goldberg - IND
- William Link - IND
- Jason Tester - IND
- Wendy Yarno - IND